Emerging tools and technologies that enhance the scientific process are driving the transformation of laboratories across the life sciences sector. Artificial intelligence (AI) is becoming a driving force in reshaping the “lab of the future,” but its benefits and limitations must be considered.

AI generally refers to technology that mimics parts of human intelligence, such as learning from data (machine learning), understanding language (natural language processing), recognizing images (computer vision) and decision-making via expert systems. In laboratory environments, AI is often applied through machine learning (ML) techniques, which train computer models to detect patterns, make predictions or optimize processes based on historical data.

Specifically, drug discovery and biological research are utilizing machine learning to identify potential drug targets, annotate genes, predict toxicity and aid in the classification of molecular structures; however, there are limitations. Models depend heavily on the quality and diversity of training data and are not substitutes for scientific expertise.

Automation and robotics

One of the most visible changes AI is driving is the increased use of robotics and automation in labs. These tools are helping scientists reduce repetitive tasks such as sample preparation, pipetting, and data recording. For example, modular automation platforms can integrate various lab instruments, enabling streamlined workflows that free up researchers to focus on higher-order experimental design and analysis.

Even as automation increases, human oversight remains essential. Current systems primarily operate under predefined instructions. A fully autonomous experimental design, where AI independently interprets results and plans follow-up experiments, is still in its early stages and remains a significant technical challenge.

Lab digitization and data optimization

Alongside robotics, digitization is reshaping how data is managed and interpreted. Data curation, integration and visualization are examples of how labs are optimizing resource use and reducing operational inefficiencies. Whereas predictive analytics can identify trends that inform experimental design or flag anomalies in equipment performance or assay results.

These technologies, while promising, also introduce new dependencies on IT infrastructure, data standardization and user training. The challenge for many organizations lies in integrating AI tools with existing systems in a way that adds value without disrupting daily workflows.

AI in drug discovery and design

The potential of AI in drug discovery has garnered substantial attention and investment. Algorithms are being developed to screen ultra-large chemical libraries, prioritize compounds for synthesis and predict binding affinities between molecules and target proteins. In fragment-based drug discovery, AI is increasingly being used to generate hypotheses for molecule design and to simulate potential interactions.

However, success in this area depends on harmonizing AI outputs with synthetic feasibility and medicinal chemistry insight. Generating a novel compound computationally is only the first step, but determining whether it can be practically synthesized and developed into a drug requires human intervention and expertise.

Regulatory, IP and implementation challenges

AI also raises questions about intellectual property. How do organizations establish unique IP for compounds discovered or designed by algorithms? The evolving patent landscape is still catching up with the nuances of algorithm-driven innovation.

In clinical applications, despite the enthusiasm for AI-assisted diagnostics and personalized medicine, real-world adoption has been slow. Technical validation, ethical considerations and the trust of physicians and patients all play critical roles in the successful implementation of AI tools in healthcare settings.

AI is a tool, not a replacement

AI and related technologies are contributing to the transformation of laboratories, particularly through automation, digitization and data analytics. These technologies offer meaningful opportunities to improve efficiency, scale experimentation and accelerate discovery. However, AI is not a silver bullet. Its effectiveness depends on data quality, thoughtful integration and human oversight.

Rather than replacing scientists, AI is most valuable as a tool that supplements their capabilities by supporting better decisions, optimizing processes and expanding the range of possibilities in research. As life sciences companies continue to explore these tools, the most successful applications will be those that combine computational power with human intelligence.